LLY

1,000.71

-0.48%↓

JNJ

244.74

-0.77%↓

ABBV

235.52

+0.85%↑

NVS

164.63

+0.55%↑

AZN

202.28

+0.84%↑

LLY

1,000.71

-0.48%↓

JNJ

244.74

-0.77%↓

ABBV

235.52

+0.85%↑

NVS

164.63

+0.55%↑

AZN

202.28

+0.84%↑

LLY

1,000.71

-0.48%↓

JNJ

244.74

-0.77%↓

ABBV

235.52

+0.85%↑

NVS

164.63

+0.55%↑

AZN

202.28

+0.84%↑

LLY

1,000.71

-0.48%↓

JNJ

244.74

-0.77%↓

ABBV

235.52

+0.85%↑

NVS

164.63

+0.55%↑

AZN

202.28

+0.84%↑

LLY

1,000.71

-0.48%↓

JNJ

244.74

-0.77%↓

ABBV

235.52

+0.85%↑

NVS

164.63

+0.55%↑

AZN

202.28

+0.84%↑

Search

CytomX Therapeutics Inc

Abierto

SectorSanidad

4.97 -1.39

Resumen

Variación precio

24h

Actual

Mínimo

4.78

Máximo

5.11

Métricas clave

By Trading Economics

Ingresos

-14M

-14M

Ventas

-13M

6M

P/B

Media del Sector

18.6

108.767

Margen de beneficios

-238.621

Empleados

119

EBITDA

-13M

-14M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+77.9% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

297M

945M

Apertura anterior

6.36

Cierre anterior

4.97

Noticias sobre sentimiento de mercado

By Acuity

57%

43%

290 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

CytomX Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 mar 2026, 18:43 UTC

Noticias de Eventos Importantes

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3 mar 2026, 17:33 UTC

Adquisiciones, fusiones, absorciones

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3 mar 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3 mar 2026, 23:44 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3 mar 2026, 23:25 UTC

Charlas de Mercado

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3 mar 2026, 23:25 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

3 mar 2026, 22:38 UTC

Noticias de Eventos Importantes

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3 mar 2026, 22:16 UTC

Ganancias

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3 mar 2026, 22:09 UTC

Ganancias

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3 mar 2026, 22:06 UTC

Ganancias

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3 mar 2026, 22:05 UTC

Ganancias

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3 mar 2026, 22:03 UTC

Ganancias

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3 mar 2026, 21:50 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Tech, Media & Telecom Roundup: Market Talk

3 mar 2026, 21:50 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

3 mar 2026, 21:45 UTC

Noticias de Eventos Importantes

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3 mar 2026, 21:37 UTC

Ganancias

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3 mar 2026, 21:26 UTC

Noticias de Eventos Importantes

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3 mar 2026, 20:31 UTC

Charlas de Mercado
Noticias de Eventos Importantes

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3 mar 2026, 20:04 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3 mar 2026, 19:17 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold and Silver Drop as Energy Surges -- Market Talk

3 mar 2026, 18:43 UTC

Ganancias

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3 mar 2026, 18:29 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Global Energy Roundup: Market Talk

3 mar 2026, 18:29 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3 mar 2026, 18:22 UTC

Noticias de Eventos Importantes

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3 mar 2026, 18:22 UTC

Noticias de Eventos Importantes

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3 mar 2026, 18:17 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3 mar 2026, 18:14 UTC

Ganancias

How Long Can Anthropic Play Defense? -- WSJ

3 mar 2026, 17:41 UTC

Noticias de Eventos Importantes

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3 mar 2026, 17:36 UTC

Noticias de Eventos Importantes

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3 mar 2026, 17:28 UTC

Adquisiciones, fusiones, absorciones

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Comparación entre iguales

Cambio de precio

CytomX Therapeutics Inc previsión

Precio Objetivo

By TipRanks

77.9% repunte

Estimación a 12 Meses

Media 9.5 USD  77.9%

Máximo 10 USD

Mínimo 7 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CytomX Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

5

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.7658 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

290 / 352 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.